T1	Participants 61 104	malignant pleural and pericardial effusion]
T2	Participants 152 185	patients with malignant neoplasm.
T3	Participants 259 287	(control group, 30 patients)
T4	Participants 337 363	(N-CWS group, 26 patients)
T5	Participants 401 475	in 55 patients with malignant pleural effusion due to primary lung cancer.
T6	Participants 857 913	Twenty-four patients with malignant pericardial effusion
